tion Agency; CPSC, Consumer Product Safety Commission; IPCS, International Programme on Chemical Safety; ADI, allowable daily intake; NOAEL, no observed adverse effect level; IRIS2, Integrated Risk Information System; ALS, amyotrophic lateral sclerosis; RfD, reference dose; LOAEL, lowest observed adverse effect level; UFs, uncertainty factors; MF, modifying factor; AUC, Area under a concentration -time curve; BMD, benchmark dose; 5HT, serotonin; MDMA, methylenedioxymethamphetamine; 3SD, three standard deviations (abnormal effect); MPTP,1-methyl-4-phenyl-1 ,2,3,6-tetrahydropyridine.
increased pressure for a more thorough screening for a wide variety of neurotoxic end points and an interpretation of the significance of effects on the nervous system, particularly in the context of premarket testing and quantification of neurotoxic risks that could contribute to setting overall priorities for risk reduction. This historical overview will explain how the professional community came to the current conception of the problem, how methodologies have evolved to meet the changing needs of decision makers, and how problem definitions and research techniques need to change further, both to meet future decision-making needs and to take advantage of opportunities to develop a fuller understanding of neurotoxic risks.
Risk assessment is the attempt to predict the likelihood that an agent will produce adverse effects in humans, typically from information obtained in animals. Assessment of risk dates from historical times, as it became the responsibility of authorities to protect its charges. However, it was not until recent times that this responsibility became formalized. The increase in the number of chemicals to which people are exposed, the numbers of cases of adverse effects of those exposures, the different type of adverse effects, and the increased precision with which levels of compounds that may be related to those effects are assayed has placed an increased level of responsibility on the process of risk assessment.
Emergence of Neurobebavioral Toxicology
During the last 30 years, there has been a sharp increase in regulatory activity by various governmental agencies to protect the population from toxic agents. This regulatory emphasis is based on several factors, including the demonstrated causal relationships between adverse health outcomes and occupational/environmental exposures, realization of the pervasive presence of environmental exposures because of increased analytical chemical capabilities, and the concern that many chemicals in the environment have not been tested for potential toxicity. In the United States, at the federal level, four regulatory agencies have been given primary responsibility for regulating exposures to toxic chemicals: the U.S. Food and Drug Administration (FDA) (most food, drug, and cosmetic exposures), the Occupational Safety and Health Administration (OSHA) (workplace exposures); the U.S. Environmental Protection Agency (U.S. EPA) (air, water, pesticides, and miscellaneous exposures to industrial chemicals-the latter via the Toxic Substances Control Act), and the Consumer Product Safety Commission (CPSC) (1) . Premarket screening is generally conducted for new food additives, drugs, pesticides, and some industrial chemicals when there is reason to suspect that anticipated use may pose unreasonable risks. In addition there is a provision for requiring testing of chemicals that are already on the market in the case of pesticides (on reregistration) and selected industrial chemicals. Similar requirements are present in a number of other countries.
Since 1975, several expert panels have recommended that regulatory agencies should screen chemicals for neurotoxicity; many of these recommendationsspecifically stated that neurobehavioral end points such as neurological functioning, motor activity and schedule-controlled behavior, be used in neurotoxicity hazard identification (2) . Behavioral procedures are currently employed to evaluate developmental neurotoxicity of drugs in Japan and the European Union (3), while neurotoxicity testing protocols are being considered by the Organization of Economic Cooperation and Development (4) . The International Programme on Chemical Safety (IPCS) has recommended that chemicals be evaluated for potential neurotoxicity using behavioral tests (5) and is currently sponsoring a collaborative study to validate the use of a neurobehavioral screening battery for the routine assessment of chemicals for neurotoxicity (6) . Testing guidelines for several neurobehavioral end points, including some from developmental neurotoxicity, have been published by the U.S. EPA (7) . Neurobehavioral measures are also used in neurotoxicity hazard identification by other regulatory agencies in the United States, including the FDA, OSHA and CPSC (8) . Neurobehavioral end points are frequently used in conjunction with other measures of neurotoxicity such as neuropathology and neurochemistry in an integrated approach to assess chemicals for possible neurotoxicity (7) .
The development of quantitative methods in neurobehavioral toxicity assessment clearly has its roots in behavioral pharmacology. Pavlov, Skinner, and Freud each contributed in their own way to the assessment of the behavioral effects of agents, and, as this type of analysis grew, behavioral pharmacologists quickly learned the value of complete dose-effect data from pharmacologists. While the era of quantitative analysis of behavioral pharmacology data was ushered in by the seminal work of Dews (9) , quantitative work in behavioral toxicology closely followed. In one of the first demonstration of these methods Armstrong et The overwhelming majority of current attempts to quantify risk are based on concepts developed over 40 years ago in which a specific number, the allowable daily intake (ADI) is derived from experimental data to determine safe levels for regulatory purposes (11) . As updated in present usage this approach is essentially based on finding a dose that does not produce an adverse effect in an experimental system (the no observed adverse effect level NOAEL) and that uses uncertainty factors to account for considerations such as differences between humans and animals, differences among humans in individual sensitivity, possible interactions between chemicals in the diet, and various departures from ideal quality and coverage of sensitive end points in the data base. The ADI is intended to represent the dose rate for a chemical (in mg/kg body weight/day) that is likely to be without appreciable risk of deleterious effects during a lifetime of exposure.
At the present time, risk assessment guidelines published by the CPSC (12) , and under review by the U.S. EPA, discuss several techniques to obtain a quantitative estimate of risk. In spite of the lack of formal risk assessment guidelines, the U.S. EPA has used neurotoxic end points to make regulatory decisions for a substantial number of chemicals. For example, the EPAs Integrated Risk Information System (IRIS), which contains information on regulatory decisions made by the agency, indicates that approximately 20% of the nearly 550 standards or advisories in the database are based wholly or in part on neurotoxic end points. Approximately one half of the neurotoxic end points used were neurobehavioral effects, including neurological signs, changes in motor activity, and altered sensorimotor function (13) .
In recent years there have been increased pressures for quantification of risk levels arising from a) the desire to evaluate the health benefits in some terms that can be compared with economic costs of regulatory control actions, b) priority ranking schemes to direct agency attention to arguably more significant problems (14, 15) and c) needs for more quantitative assessments of significance in the context of ecological risk assessment.
Finally, advances in our scientific understanding now indicate that some neurotoxic effects in the human population may be subtle but significant. Such Guideline Use a 10-fold factor when extrapolating from valid experimental results from studies using prolonged exposure to average healthy humans. This factor is intended to account for the variation in sensitivity among the members of the human population. Use an additional 1 0-fold factor when extrapolating from valid results of long-term studies on experimental animals when results of studies of human exposure are not available or are inadequate. This factor is intended to account for the uncertainty in extrapolating animal data to the case of average healthy humans. Use up to an additional 1 0-fold factor when extrapolating from less than chronic results on experimental animals or humans when there are no useful long-term human data. This factor is intended to account for the uncertainty in extrapolating from less than chronic NOAELs to chronic NOAELs. Use up to an additional 1 0-fold factor when deriving an RfD from a LOAEL instead of NOAEL. This factor is intended to account for the uncertainty is extrapolating from LOAELs to NOAELs. Use professional judgment to determine another uncertainty factor (MF) that is less than or equal to 10 . The magnitude of the MF depends upon the professional assessment of scientific uncertainties of the study and data base not explicitly treated above, e.g., the number of animals tested. The default value for the MF is 1.
OAdapted from Barnes and Dourson (15) .
to account for the incompleteness of the data set (17) . from the data set, and the NOAEL/LOAEL must be one of the doses used in the experiment. It is, therefore, possible that the number and spacing of doses in a study could affect the dose eventually selected as the NOAEL. As shown by Kimmel (17) , a NOAEL could vary by a factor of 3 depending on the doses used in the experiment.
A potential problem with the RfD approach is that it does not take into account the shape of the dose response curve. Crump (18) The RfD approach also does not take into account the statistical uncertainties in determining the NOAEL from the experiment. For example, using a larger number of subjects per group increases the power of the experiment to detect an effect with statistical significance at a lower dose. Therefore, using larger groups of animals would tend to lead to a lower RfD. Similarly, measures having an inherently high baseline incident of a toxic effect could result in higher RfDs than measures that have a lower baseline effect incidents.
The RfD also makes the assumption that there is no increase in the incidence of toxicity over background at exposure levels at or below the RfD. It does not, therefore, provide for a procedure to determine risk at any other dose. This is particularly problematic if it is desired to assess a) the increase in risk that may be present if exposure occurs slightly above the RfD, or b) the confidence that a decision maker should place in the estimate that risk (incidence of effect) will be below specific numerical targets (or, conversely, the degree of uncertainty that might exist that risk might be above desired target levels).
There is at present no distinctive treatment of neurobehavioral effects in this process. Developmental effects are sometime given an extra factor although there is no general policy. For the long-term future development of neurobehavioral toxicology and decision making, the simple uncertainty factor approach has a number of other disadvantages (19):
* No one knows how protective the RfD really is, either in general or in specific cases. What fraction of the diverse human population can be expected to experience adverse effects when exposed at the level calculated to be acceptable under the formula? In general, there may be some finite fraction of individuals who, because of disease or other causes, are marginal for biological functions affected by the chemical and who may be pushed beyond a functional threshold for an adverse effect by a small finite dose of the chemical. For example, for healthy workers there may indeed be a functional reserve capacity for oxygen delivery to the myocardium and hence a finite tolerance for a small impairment of oxygen-delivering capacity for the blood due to carbon monoxide. However, for a worker who has just begun to experience a myocardial infarction, oxygen delivery to portions of the myocardium is known to be seriously compromised, and it is possible that a small difference in oxygen delivery capacity due to a modest blood carboxyhemoglobin concentration could prove the difference between life and death for portions of the heart muscle that are suddenly forced to rely on collateral arterial vessels for oxygen supply (20) . bThe numbers are the ratios of the value of each parameter for the 95th percentile individual to the value of the parameter for the 5th percentile individual (see Figure 1 for illustration), based on the assumption that the values of the parameter are lognormally distributed (that is, the logarithms of the parameter values are normally distributed). cData from Hattis et al. (21) . dData from Hattis et al. (22) . "Data from the National Academy of Sciences ( 19). fData from Hattis and Silver (23) and Hattis (24) . Caveat: Imperfection of the dosimeter used here (maternal hair mercury) may have led to serious overestimation of the actual extent of interindividual variability.
Width of the 90% range it Table 2 Ez 5~~~~~~~~~~~5% Log (toxin elimination rate) In particular, it is also likely that the inability of the uncertainty factor paradigm (as usually formulated) to incorporate newer types of relevant information into a systematic procedure for updating assessments of health hazards has tended to discourage both the collection and analysis of potentially important data. One example of this is information on human interindividual variability in parameters that could affect susceptibility. Gaylor/Slikker. Gaylor and Slikker (26) have proposed an approach to risk assessment that is based on the control variability of the measure of interest. In their preliminary presentation of the method, an example in which monkeys were treated with MDMA was used to demonstrate the risks of decreasing serotonin (5HT) levels. In that example, the normal variation in 5HT was determined from a control sample, and a level of 3 standard deviations (SD) was used as a metric to define an abnormal level of 5HT. The effects of several treatments with different dose levels of MDMA served to establish a dose-response function for the relationship between the decrease in 5HT as a function of MDMA treatment. On this dose-response function, a dose was chosen as one for which risks would be determined. The assumption that variation in levels of 5HT after this treatment was applied to the mean effect, obtained from the function, and the overlap of this distribution with the level at which 3SD in the control data provided an indication of the proportion of the population expected to be affected abnormally at that dose. The method is easily adapted to assessing the increase in risk posed by progressively smaller doses by comparing similar distributions of effect, until the additional area (over background) under these distribution curves beyond the 3 SD cutoff is as small as 1/100 or 1/1000.
The method has not been used extensively to fully evaluate potential concerns. One concern that has been voiced, however, is that the assumption that variability in effect exhibited at an interpolated dose should be measured rather than assumed. The use of assumed variability measures at very low doses may also preclude the ability to realistically predict effects at low doses. A clear advantage of the method is that it unambiguously defines an abnormal effect (3 SD) , and as such may be useful in adapting risk assessment procedures to continuous variables that do not span a range that can be characterized by traditional scales.
Dews/Glowa. Dews (27) (18) was chosen and the mean and distribution of the effect was characterized. Dews assumed that these individual differences in effect (or a log transformation) would be normally distributed. By making this assumption, it was easy to compare the distribution of expected effects using normal curve statistics (i.e. the probability of an effect in the population is distributed as a Z-score). By selecting a probability of interest (e.g., 1/10, 1/100, or 1/1000), the intercept of that point on the distribution with the abscissa specifies the dose at which that incidence of effect is expected.
The method has the advantage of being simple and relatively independent of the type of function chosen to represent the individual dose-effect functions. It also is one of the few methods that actually determines a population-sensitivity measure and uses it for risk assessment. The assumption that the doses producing specific amounts of effects are normally or lognormally distributed is an additional benefit, because a great deal is known about the normal curve, in contrast to the fact that we know very little about the shape of the dose-effect function at low levels. The level chosen is somewhat arbitrary, but 10% usually lies within the directly measurable portion of the curve.
A distinct disadvantage of the approach originally described by Dews (27) Probit and Logit Tolerance Distribution Models. When the available data on effects are quantal (plus/minus; cases/noncases) and the primary issue for analysis is the spread of interindividual variability in a population, log probit and logit dose-response functions may be appropriate. Both the log probit and the logit are tolerance distribution models: they are based on the assumption that the effect in question is produced in different individuals when individual threshold doses are exceeded. In the case of the log probit model, these threshold doses are assumed to be lognormally distributed in the exposed population (that is, the logarithms of the threshold doses for individual people/animals are assumed to have a normal gaussian distribution). In the case of the logit model, the population distribution of thresholds is assumed to correspond to a logistic function.
In practice there is very little difference in the dose response projections made using these two models for effect incidences between 1 and 99%. The logistic model has slightly broader tails and therefore makes somewhat larger predictions of low dose risks when projections are made from high-dose observations. A report by the U.S. National Academy of Sciences (19) has a comparison of low dose predictions of risks from fetal developmental exposure to methylmercury using the logit (28) and log probit models, as applied to the human data from the mass poisoning episode in Iraq (29) . At a dose predicted by the logit model to produce a 0.5% incidence of late walking in gestationally exposed offspring, the probit model prediction was for a 0.25% incidence of the effect.
The logit model tends to be favored by statistically oriented workers because of its computational convenience in fitting data. The traditional maximum likelihood procedure of Finney (30) often used to fit the log probit function, is by contrast relatively cumbersome, although automated routines are available. The rationales advanced by advocates of the probit model include a) at least a vague mechanistic foundation (a lognormal distribution of thresholds would be expected to be produced if there were several factors that contributed to interindividual differences in sensitivity and if these factors tend to act multiplicatively in determining individual thresholds); and b) a long history of prior usage in the traditional analysis of animal dose-response data (most notably in the calculation of LD50 values). For example, Gaddum (31) (32) .
Given that some effects are produced by individual threshold processes, the probit model offers a direct opportunity to assess the spread of the population distribution of the thresholds. The estimated SD of the population distribution of the logarithms of the thresholds is the reciprocal of the probit slope in conventional plots of the probit of response versus log dose (24) Some features of neurotoxic effects that are amenable to quantitative dynamic modeling at the present time are * The ability to establish definitive relationships between external dose and the internal dose-time profile at the presumed site(s) of action for some chemicals. This is best done using the well-developed paradigm of physiologically based pharmacokinetic modeling (33, 34) , which has been extensively used in carcinogenesis risk assessment in recent years (35) . The importance of good active site dosimetry is to separate nonlinearities of pharmacokinetic origin from nonlinearities arising from fundamental neurotoxic processes in the chain of events leading from external exposure to the production of neurobehavioral responses * The familiar tools of MichaelisMenten enzyme kinetics are readily adaptable to elucidating the dose response relationships for both saturable transport processes and the inhibition of enzymes that are important for the survival and functioning of cells in the nervous system (36) .
* The accumulation and repair of reversible neurotoxic damage can be presented in pharmacodynamic models in some cases (37) .
Reference (24) includes some more exploratory uses of mechanistic models for the central processes involved in neurotoxicity including a) chronic accumulation of irreversible damage via the loss of neuronal cells; b) the use of intermediate biomarkers along the causal pathway to neural dysfunction to aid in dose-response and population effects modeling (38) ; and c) the implications of the structural features of neuronal systems (e.g., redundancy, series arrangement of cells performing functions, plasticity) for the relationships between dose-response relationships for the inhibition of neurobehavioral function and dose response relationships for the inhibition of individual neurons.
Recommendations for Assessing New or Old Agents with Good Data
The previous sections have described the generic advantages and disadvantages of several quantitative risk assessment methodologies. The current section will attempt to apply these models to various types of data sets that may be encountered in the risk assessment process. In this section it is assumed that some hazard identification has already occurred and that the risk assessor is presented with a set of data requiring a risk assessment decision. A preliminary assessment of the data set has indicated that a neurobehavioral effect is the critical end point and quantitative risk assessment should proceed using these data.
Typically the first step in the process is to identify the relevant toxicity studies and the supporting data that can be used to select and modify the best approach for the generation or application of a doseeffect function. The most usable types of dose-effect functions are those that clearly delineate control variability and assess a sufficient number of doses to a) establish a NOEL/NOAEL or a benchmark dose, b) characterize the slope of the dose-effect function; and, ideally, c) relate to potentially of an effect may not be sufficient to assess risks quantitatively.
Examples
As with the RfD approach, several features of the type of end point used for assessment, the nature of the control data, the experimental design (e.g., number of doses, times), variability in effect, and mechanistic information can contribute to the risk assessment process using quantitative methods. In an effort to present the role of these variables and the possible use of the different quantitative methods under different conditions, the following representative examples of datasets are presented: a) A developmental study was conducted in which groups of pregnant rats were treated with a penicillin derivative (100, 500, and 2000 mg/kg, po) and a control group was treated with vehicle during days 6 to 15 of pregnancy. A typical battery of developmental end points was assessed, and changes in these variables were used as a covariate in the determination of significant neurobehavioral effects. In this study a significant change in activity was found at the highest dose as determined using concurrent and historical control levels of activity. The dose had no toxic effects on the mother. Additional information came from a placental transfer study that established embryo-fetal exposure over the whole dose-range studied and from a pharmacokinetic study in pregnant animals that showed a linear increase in plasma levels up to the highest dose.
This developmental study provided good dose-effect data and a range of normal control data, allowing each of the methods to be applied. An RfD could be calculated based on the next-to-highest dose being chosen as a NOAEL, as it did not produce observable effects. This would, under the current example, produce an RfD that was considerably below therapeutic levels, indicating that at therapeutic levels some risk was present. The calculation of a risk figure by each of the other methods would also likely point to a dose of penicillin that might be expected to exhibit developmental risk at therapeutic levels. Use of the probit model for this purpose would be marginal, however, since it would require an assumption about the probit slope, and there is only one positive dose.
Risk assessment for medicinal products rarely involves the definition of a dose that is regarded as virtually safe. The ultimate requirement is that the minimal therapeutic dose (concentration of active substance in most cases) doses not pose an unreasonable risk to the patients in relation to the anticipated therapeutic benefits. Preclinical studies, although generally referred to as safety testing, will be directed, therefore, at detecting and characterizing adverse effects with the aim of enabling the investigators to assess/quantify risks at therapeutic dose levels. During the preclinical phase of pharmaceutical testing the key elements of risk assessment for neurobehavioral/neurotoxic end points involve judging the relevance of findings to humans, considering the biological properties of the animal models used. b) In another study, a collection of case reports in which an increased incidence of neurological symptoms associated with eosinia myalgia were noted in several countries where a tainted tryptophan product had been sold. Because this data set involved simply the observation that an increased incidence of effect was seen in an exposed population and neither dose-effect nor control data were available, none of the methods are applicable; more data would be required. c) A case-control epidemiological study involved subjects with neurotoxic signs suspected to have resulted from deltamethrin (pyrethroid insecticide) exposure. Subjects matched for age, living standards, and other health and socioeconomic factors were used as controls. Effects were determined by clinical assessment, exposure was determined by questionnaire. Because individuals in the control group in case-control studies are potentially exposed (yet unaffected) and it may be difficult to establish dose-effects in the exposed group, this is a potentially difficult design to use for risk assessment. However, if a stratified analysis reveals that effects increased over a range of exposures it may be possible to apply the benchmark methods or other dose-time-response models, ideally with corrections for the biasing effects of inaccuracies in the estimation of exposures (23) .
d) In an occupational workplace study blood levels of toluene were determined directly after testing using an automated neurotoxicology test battery. Populations from several sites at the factory were tested, providing several ranges of level and including a nonexposed control. The performance deficits on the battery were positively correlated with hippuric acid level.
This workplace study would provide good effect and dose data, good characterization of human pharmacokinetics, and at least some preliminary hypothesis generation for neurotoxic mechanisms, allowing each of the methods to be used. e) A dose-response study in rats was designed to characterize acute effects of alprazolam on activity. Rats were placed in activity monitors once daily until stable baselines were established. Animals were given vehicle and different doses on separate widely spaced occasions until individual dose-effect curves were established for 10 animals. Control variability was approximately 10%. Activity was unaffected at the lowest dose tested and abolished at the highest dose tested.
This dose-response study would provide good effect and dose data, allowing each of the methods to be used. Since individual animal variability is directly assessed in this study, the method of Dews provides the most direct measures of risk. Probit and mechanistic analyses may also be possible.
f) Another dose-response study in rats was designed to characterize acute effects of MPTP on activity. Four groups of six rats each were treated with vehicle or with one of three doses of MPTP and tested three days later. Levels of activity were 200 photocell counts/15 min session in the control group, and they progressively decreased in a dose-related manner in each of the experimental groups. Variability was essentially the same in each of the groups.
This type of study would provide good effect and dose data, allowing each of the methods to be used. Since variability in effect was comparable between control and dosed groups, the method of Gaylor/Slikker could be applied without reservation. Because some aspects of the mechanism of action of MPTP have been characterized (e.g., loss of neurons relevant to some functions) a quantitative mechanistic analysis may also be possible. g) Finally one study assesses the effects of chronic (90-day) exposure to n-hexane (0, 100, 300, 1000 ppm) using a functional observational battery (FOB) either the appearance or the disappearance of the functional changes.
It is obvious that each of these quantitative risk assessment methods can be used under various conditions with different types of data and, also, some methods are inappropriate with some types of data. The applicability of the different models to the different data sets as described is summarized in Table 3 . When faced with these types of choices, the risk assessor may be compelled to chose a method with which he/she is most familiar or one that produces the most conservative risk figure. Since few studies have directly compared these different methods using the same data set, such choices may be less than ideal. Rather, it may be more instructive to compare the figures produced by each to understand the methods better.
With the possible exception of the probit and mechanistic models, virtually none of the methods conceived after the development of the RfD actively contribute to the exploration of the effectiveness or necessity of uncertainty factors. Crump (18) and Gaylor and Slikker (26) explicitly state that uncertainty factors have to be added to the number produced by their methods. Dews (27) discusses the possibility of finding species more and less susceptible than humans and interpolating rather than extrapolating for interspecies differences. Many of these methods, especially that of Dews (27) It is now evident that the presence of developmental neurotoxicity may depend on the specific periods of nervous system development (42) . In addition, the results of early developmental exposure may become evident only as the nervous system matures and ages. With aging, the level of risk for a number of health-related factors increases and it is possible that the risk for toxic insult to the nervous system may also increase. It has been hypothesized that the aging nervous system may have a decreased ability to compensate for toxic insults and that exposure to neurotoxicity could increase the rate of age-related neuronal cell loss (43) . Examples of other possible susceptible populations include individuals having neurodegenerative disorders such as Parkinson's or Alzheimer's Disease, those with nutritional deficiencies and certain ethnic groups. Gender-dependent responses to neurotoxicants have also been noted.
Most current standard risk-assessment methodologies attempt to correct for differences in susceptible populations by using an uncertainty factor for within population variability. Whether a factor of 10 or less is sufficient to protect against the differential sensitivity of different groups is not known, and the risk assessor should be aware that qualitative, as well as quantitative, differences could affect the risk assessment process.
Shape of the Dose-Response Curve. Many of the methods used in quantitative risk assessment assume a linear or sigmoidal monotonically increasing dose-response curve. However, inverted U-shaped doseresponse curves are sometimes observed in neurobehavioral studies. For example, it is sometimes observed that an agent will increase the frequency of a response, such as motor activity or schedule-controlled behavior, at low doses while decreasing responses at higher doses. In such cases, it may be difficult to determine which part of the dose-response curve should be used in quantitative risk assessment. The risk assessor should be aware that different critical effects could be obtained depending on the arm of the dose-response curve which is selected and that some quantitative methodologies will not be appropriate for such data.
During the process of risk recognition and from attempts to test for risk routinely to prevent or regulate exposure to neurotoxicants, we appear to have discovered valuable information about the behavior of investigators and risk assessors. In brief, there appears to be less interaction than would be desirable.
Summary
The concept of risk as it relates to neurobehavioral toxicology has evolved over time. Guidelines for how to test chemicals for neurotoxicity are being followed by risk assessment guidelines. The focus in research has shifted from qualitative risk assessment, i.e., hazard identification, to quantitative risk assessment, i.e., how to predict risk based on available data.
Several quantitative models of risk assessment have been proposed during the last several years. The traditional default approach, i.e., the RfD, is based on the allowable daily intake hypothesis proposed over 40 years ago. Risk assessors are now confronted with a wide array of risk assessment methodologies, each having their own advantages and disadvantages, depending upon the experimental design and characteristics of the dataset.
Current risk assessments using neurobehavioral data face several problems that could confound the interpretations of the result, including reversibility of effect, susceptible populations, multiple end points, and the shape of the dose-effect curve. Clearly, the state-of-the science for quantitative risk assessment of neurotoxicity is evolving and can be improved only through additional research.
